Showing results (691-700 of 835) with videos related to

Sort By:
Pageof 84
Pediatric Blood & Cancer|December 18, 2009
Initial testing of topotecan by the pediatric preclinical testing programHernan Carol, Peter J Houghton, Christopher L Morton, et al.
Blood Advances|April 6, 2026
Cure Sickle Cell Initiative Recommendations on Common Data Elements for Sickle Cell Disease Gene Therapy TrialsSophie Lanzkron, Victoria H Coleman-Cowger, Alexis A Thompson, et al.
Pediatric Blood & Cancer|March 2, 2011
Initial testing of lenalidomide by the pediatric preclinical testing programC Patrick Reynolds, Min H Kang, Stephen T Keir, et al.
Protein Expression and Purification|October 30, 2016
Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from Leishmania donovani, a vaccine candidate for preventing cutaneous leishmaniasisC Patrick McAtee, Christopher A Seid, Molly Hammond, et al.
Pediatric Blood & Cancer|September 25, 2012
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing programC Patrick Reynolds, Min H Kang, Hernan Carol, et al.
International Journal of Environmental Research and Public Health|January 1, 2021
Perceptions and Experiences of the University of Nottingham Pilot SARS-CoV-2 Asymptomatic Testing Service: A Mixed-Methods StudyHolly Blake, Jessica Corner, Cecilia Cirelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2002
Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption ConsortiumNancy D Doolittle, Lauren E Abrey, Nicolay Ferrari, et al.
Pediatric Blood & Cancer|November 22, 2011
Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing ProgramRichard Gorlick, John M Maris, Peter J Houghton, et al.
Pediatric Blood & Cancer|October 27, 2009
Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing programMalcolm A Smith, Christopher L Morton, E Anders Kolb, et al.
Pediatric Blood & Cancer|October 22, 2008
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology GroupJulie R Park, Judith G Villablanca, Wendy B London, et al.
Pageof 84